DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial.

3 juillet 2023

June, 20, 2023: DELPHARM and CREAPHARM announced today that they have combined their expertises to synergistically support
HMNC Brain Health, a global clinical-stage biopharmaceutical company pioneering the development of personalized
therapies in psychiatry. On June 20, 2023, HMNC announced enrollement of the First Patient In (FPI) in Phase 2, PoC trial in more than 300 patients with Major Depressive Disorder (MDD) conducted in eight countries in Europe.
This trial is a crucial component of the Nelivabon program, one of HMNC Brain Health’s flagship precision psychiatry programs,
aimed at developing BH-200, a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who
have underlying HPA-axis (Hypothalamus‐pituitary‐adrenal axis) dysfunction. Moreover, it will test the predictive capabilities
of the V1b polygenic score, which the company aims to eventually develop into a companion diagnostic for BH-200. To know more